Efficacy and the Safety Study of RD94 in Patients With Endodontic Care (RD94)

July 23, 2013 updated by: Ascopharm Groupe Novasco

Open Trial, Not Randomized Study Evaluating the Efficacy and the Tolerance of RD94 in Patients Needing Endodontic Care, Medical Device Class III

TRIAL TITLE Open trial, not randomized study evaluating the efficacy and the tolerance of RD94 in patients needing endodontic care, medical device class III.

SPONSOR:

SEPTODONT, 58 rue de Pont de Créteil, 94107 Saint Maur des Fossés cedex Tel : + 33 1-49-76-74-26, Fax. : + 33 1- 49-76-71-91

Reference protocol: 09/001

PRODUCT NAME: Biodentine™ (RD94)

MEDICAL DEVICE:

Class: Bioactive dental substitute (Tricalcium silicate) Dose: not applicable Application : one single time

DEVELOPMENTAL PHASE: not applicable (medical device class III)

Study Overview

Status

Completed

Conditions

Detailed Description

METHODOLOGY:

This multi-centre and open-label study comprises six groups corresponding to the six indications tested. No placebo or reference product is involved. No randomization is required as the indication will define the patient selection.

The six indications studied are:

  • Direct pulp capping following carious pulp exposure
  • Direct pulp capping following dental trauma injury to healthy pulp (partial pulpotomy)
  • Repairing perforated root canals and/or the pulp chamber floor
  • Retrograde endodontic surgery
  • Pulpotomy in primary molars
  • Apexification

Study start: October 2009

Inclusion period: 1/10/2009 to 30/06/2011

Study duration: 2 years

OBJECTIVES:

The trial objective is to illustrate the clinical efficacy and tolerance of RD94 in the indications described.

Primary objective:

The primary objective is to show that RD94 can be easily applied in the claimed indications and to evaluate its efficacy. This can be defined after a 6 month follow-up.

Secondary objective:

The secondary objective is to evaluate the efficacy of RD94 after a two year follow-up which is important for safety and the longevity of the product.

TRIAL POPULATION AND NUMBER OF PATIENTS:

60 patients in three French study centers, 10 per indication studied. Depending on the indication, children (from 3 years onwards), and/or adults will be included.

DURATION OF TREATMENT:

The product is applied on D0 (Inclusion) of the study. The follow-up period includes 2 years with six visits: Visit1 - Week 1, Visit 2 - Month 1, Visit 3 - Month 3, Visit 4 - Month 6, Visit 5 - Year 1, Visit 6 - Year 2.

Study Type

Interventional

Enrollment (Actual)

53

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France
        • Cabinet de Chirurgie Dentaire rue Saint Didier
      • Paris, France
        • Service d'endodontie de la Pitié Salpêtrière Hôpital de la Pitié Salpêtrière
      • Paris, France
        • Service d'Odontologie Hôpital Rothschild

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 months and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

  • provide signed, informed consent.
  • be affiliated to social security. criteria for the corresponding indication: Direct pulp capping following carious pulp exposure - children (6 to 18 years) + adults
  • Symptomatic or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.

Direct pulp capping following dental trauma injury to healthy pulp, reformulated as a partial pulpotomy - children (6 to 18 years) + adults

- Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.

Repairing perforated root canals and/or the pulp chamber floor - adults

  • Iatrogenic perforation of the pulpal floor, with or without LEO.
  • Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.
  • Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO.

Retrograde endodontic surgery - adults

  • Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.
  • Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option.

Pulpotomy in primary molars - children ( 3 to 12 years )

  • Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.
  • Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years.

Apexification - children (7 to 18 years) + adults

  • Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.
  • Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.
  • Apical Root Resorption

Exclusion Criteria

  1. History of malignancy in the last 5 years.
  2. Systemic disease not stabilized within 1 month before the Inclusion Visit or judged by the investigator to be incompatible with the study or condition incompatible with the frequent assessments needed by the study.

3 Risk A cardiopathies 4. Known hypersensitivity to one of the components of the study or procedural medications.

5. Presence or history of severe systemic allergy. 6. Presence or history of drug addiction or alcohol abuse. 7. Patient who has participated in a clinical trial with a new active substance during the month before study entry.

8. Participation in another clinical study at the same time as the present study.

9. Known pregnancy or lactation at study entry.

exclusion criteria for each indication : Direct pulp capping following carious pulp exposure

  • Chronic irreversible pulpitis
  • Pulp necrosis
  • Anterior or saliva-contaminated tooth pulp exposure
  • Accidental exposure occurring during non-retentive prosthetic preparation Direct pulp capping following dental trauma injury to healthy pulp, reformulated as a partial pulpotomy
  • Pulp exposure period > 72 hours
  • Crown-root fracture
  • Pulpal necrosis with or without periapical disease(LEO)

Repairing perforated root canals and/or the pulp chamber floor

  • Supracrestal iatrogenic perforation
  • Inadequate periodontal support
  • Loss of tooth structure (Coronal decay and/or concomitant root decay) compromising the tooth's maintenance on the dental arch) Retrograde endodontic surgery
  • Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, when a working coronal restoration is either missing or presents microleakage
  • Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when surgical treatment does not offer a more favorable risk-benefit ratio than the orthograde retreatment option
  • Insufficient periodontal support, endo-periodontal lesion
  • Coronal decay and/or concomitant root decay compromising the tooth's maintenance on the dental arch
  • Maxillary intrabony lesion of suspected non-endodontic origin

Pulpotomy:

  • Temporary molar expected to begin exfoliation within 24 months.
  • Molar presenting signs of irreversible pulp disease - spontaneous pain

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Direct pulp capping/carious exposure
symptomatic (provoked pain) or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
Experimental: Direct pulp capping/dental trauma
• Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
Experimental: Repairing root canals/pulp chamber floor
  • Iatrogenic perforation of the pulpal floor, with or without LEO.
  • Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.
  • Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO.
Experimental: Retrograde endodontic surgery - adults
  • Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.
  • Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option
Experimental: Pulpotomy in primary molars - children (3 to 12 years )
  • Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.
  • Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years.
Experimental: Apexification - children (7 to 18 years) + adults
  • Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.
  • Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.
  • Apical Root Resorption

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Efficacy
Time Frame: 3 months
The primary objective is to show that RD94 can be easily applied in the claimed indications and to evaluate its efficacy. This can be defined after a 3 month follow-up.
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Long term efficacy and safety
Time Frame: 2 years
The secondary objective is to evaluate the efficacy of RD94 after a two year follow-up which is important for safety and the longevity of the product.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Frédéric RILLIARD, Pr, Université Paris 7-Denis Diderot
  • Principal Investigator: Chantal Naulin-Ifi, Docteur, Service d'Odontologie du GHPS
  • Principal Investigator: Pierre Colon, Pr, Université Paris VII Garancière.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2010

Primary Completion (Actual)

April 1, 2013

Study Completion (Actual)

April 1, 2013

Study Registration Dates

First Submitted

November 6, 2012

First Submitted That Met QC Criteria

November 27, 2012

First Posted (Estimate)

November 29, 2012

Study Record Updates

Last Update Posted (Estimate)

July 24, 2013

Last Update Submitted That Met QC Criteria

July 23, 2013

Last Verified

July 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • 09/001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tooth Injury

Clinical Trials on Application of Biodentine™ (RD94), dentin substitute

Subscribe